

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

October 2011

Vol. 39, No. 10

CONTENTS

MINIREVIEW

How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential. *Eugenia Kraynov, Steven W. Martin, Susan Hurst, Odette A. Fahmi, Martin Dowty, Carol Cronenberger, Cho-Ming Loi, Bing Kuang, Owen Fields, Scott Fountain, Michel Awwad, and Diane Wang* **1779**

SHORT COMMUNICATIONS

Pharmacokinetics of Daikenchuto, a Traditional Japanese Medicine (Kampo) after Single Oral Administration to Healthy Japanese Volunteers. *Masaya Munekage, Hiroyuki Kitagawa, Kengo Ichikawa, Junko Watanabe, Katsuyuki Aoki, Toru Kono, and Kazuhiro Hanazaki* **1784**

Measurement of Binding of Basic Drugs to Acidic Phospholipids Using Surface Plasmon Resonance and Incorporation of the Data into Mechanistic Tissue Composition Equations to Predict Steady-State Volume of Distribution. *Helen Small, Iain Gardner, Hannah M. Jones, John Davis, and Malcolm Rowland* **1789**

ARTICLES

Efflux Transport Is an Important Determinant of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate Pharmacokinetics. *Maciej J. Zamek-Gliszczynski, Jeffrey S. Day, Kathleen M. Hillgren, and Diane L. Phillips* **1794**

Pharmacokinetic and Pharmacodynamic Modeling of the Effect of an Sodium-Glucose Cotransporter Inhibitor, Phlorizin, on Renal Glucose Transport in Rats. *Koji Yamaguchi, Motohiro Kato, Masayuki Suzuki, Kimie Asanuma, Yoshinori Aso, Sachiya Ikeda, and Masaki Ishigai* **1801**

Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs. *Yoshiyuki Yabe, Aleksandra Galetin, and J. Brian Houston* **1808**

Thioacetamide Intoxication Triggers Transcriptional Up-Regulation but Enzyme Inactivation of UDP-Glucuronosyltransferases. *Haiping Hao, Lifang Zhang, Shan Jiang, Shiqing Sun, Ping Gong, Yuan Xie, Xueyan Zhou, and Guangji Wang* **1815**

Bioactivation Pathways of the Cannabinoid Receptor 1 Antagonist Rimonabant. *Moa Andresen Bergström, Emre M. Isin, Neal Castagnoli Jr., and Claire E. Milne* **1823**

Pharmacokinetic Optimization of 4-Substituted Methoxybenzoyl-aryl-thiazole and 2-Aryl-4-benzoylimidazole for Improving Oral Bioavailability. *Chien-Ming Li, Jianjun Chen, Yan Lu, Ramesh Narayanan, Deanna N. Parke, Wei Li, Sunjoo Ahn, Duane D. Miller, and James T. Dalton* **1833**

Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase Inhibitor. *Lichuan Liu, Jason S. Halladay, Young Shin, Susan Wong, Melis Coraggio, Hank La, Matthew Baumgardner, Hoa Le, Sashi Gopaul, Jason Boggs, Peter Kuebler, John C. Davis Jr., X. Charlene Liao, Joseph W. Lubach, Alan Deese, C. Gregory Sowell, Kevin S. Currie, Wendy B. Young, S. Cyrus Khojasteh, Cornelis E. C. A. Hop, and Harvey Wong* **1840**

Mechanisms of Reduced Maternal and Fetal Lopinavir Exposure in a Rat Model of Gestational Diabetes. *Gregory J. Anger and Micheline Piquette-Miller* **1850**

Functional Characterization of CYP2B6 Allelic Variants in Demethylation of Antimalarial Artemether. *Masashi*

Continued on next page

- Honda, Yuka Muroi, Yuichiro Tamaki, Daisuke Saigusa, Naoto Suzuki, Yoshihisa Tomioka, Yoichi Matsubara, Akifumi Oda, Noriyasu Hirasawa, and Masahiro Hiratsuka* **1860**
- ☐ Enhancement of Oral Bioavailability of 20(S)-Ginsenoside Rh2 through Improved Understanding of Its Absorption and Efflux Mechanisms. *Zhen Yang, Song Gao, Jingrong Wang, Taijun Yin, Yang Teng, Baojian Wu, Ming You, Zhihong Jiang, and Ming Hu* **1866**
- ☐ Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats. *Jinfa Yang, Zhengping Wang, Ying Fang, Jing Jiang, Frances Zhao, Hansen Wong, Mark K. Bennett, Christopher J. Molineaux, and Christopher J. Kirk* . **1873**
- In Vitro and In Vivo Metabolism of a Selective δ -Opioid Receptor. *Jian Guo, Chungang Gu, Diansong Zhou, Charles S. Elmore, Khanh H. Bui, and Scott W. Grimm* **1883**
- Metabolite Profiles of Degarelix, a New Gonadotropin-Releasing Hormone Receptor Antagonist, in Rat, Dog, and Monkey. *Anders Sonesson, Wolfgang Koehling, Jacek Stalewski, László B. Tankó, and Birgitte Buur Rasmussen* **1895**
- Brain Regional Pharmacokinetics of *p*-Aminosalicylic Acid and Its N-Acetylated Metabolite: Effectiveness in Chelating Brain Manganese. *Lan Hong, Wendy Jiang, Hao Pan, Yueming Jiang, Su Zeng, and Wei Zheng* **1904**
- ☐ Enabling Clearance Predictions to Emerge from In Silico Actions of Quasi-Autonomous Hepatocyte Components. *Shahab Sheikh-Bahaei and C. Anthony Hunt* **1910**
- ☐ Predictive Utility of In Vitro Rifampin Induction Data Generated in Fresh and Cryopreserved Human Hepatocytes, Fa2N-4, and HepaRG Cells. *Ian E. Templeton, J. Brian Houston, and Aleksandra Galetin* **1921**
- The Impact of Hepatic Uptake on the Pharmacokinetics of Organic Anions. *Philip Gardiner and Stuart W. Paine* **1930**
- Characterization and Crystallization of Mouse Aldehyde Oxidase 3: From Mouse Liver to *Escherichia coli* Heterologous Protein Expression. *Martin Mahro, Catarina Coelho, José Trincão, David Rodrigues, Mineko Terao, Enrico Garattini, Miguel Saggi, Friedhelm Lenzian, Peter Hildebrandt, Maria João Romão, and Silke Leimkühler* **1939**
- Distribution of KAI-9803, a Novel δ -Protein Kinase C Inhibitor, after Intravenous Administration to Rats. *Yoshihiro Miyaji, Sarah Walter, Leon Chen, Atsushi Kurihara, Tomoko Ishizuka, Motoko Saito, Kenji Kawai, and Osamu Okazaki* **1946**
- ☐ Analysis of Global and Absorption, Distribution, Metabolism, and Elimination Gene Expression in the Progressive Stages of Human Nonalcoholic Fatty Liver Disease. *April D. Lake, Petr Novak, Craig D. Fisher, Jonathan P. Jackson, Rhiannon N. Hardwick, D. Dean Billheimer, Walter T. Klimecki, and Nathan J. Cherrington* **1954**
- Clearance and Biodistribution of Liposomally Encapsulated Nitroxides: A Model for Targeted Delivery of Electron Paramagnetic Resonance Imaging Probes to Tumors. *Scott R. Burks, Eric A. Legenzov, Gerald M. Rosen, and Joseph P. Y. Kao* **1961**
- Conjugation of Synthetic Cannabinoids JWH-018 and JWH-073, Metabolites by Human UDP-Glucuronosyltransferases. *Krishna C. Chimalakonda, Stacie M. Bratton, Vi-Huyen Le, Kan Hui Yiew, Anna Dineva, Cindy L. Moran, Laura P. James, Jeffery H. Moran, and Anna Radomska-Pandya* . **1967**
- Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses. *Johanna Honkalammi, Mikko Niemi, Pertti J. Neuvonen, and Janne T. Backman* **1977**
- CYP4F3B Expression Is Associated with Differentiation of HepaRG Human Hepatocytes and Unaffected by Fatty Acid Overload. *Stéphanie Madec, Virginie Cerec, Emmanuelle Plée-Gautier, Joseph Antoun, Denise Glaise, Jean-Pierre Salaun, Christiane Guguen-Guillouzo, and Anne Corlu* **1987**

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Relationship between the inhibitory effects of gemfibrozil 1-*O*- β -glucuronide on CYP2C8 and OATP1B1 activity and observed increases in repaglinide AUC_i/AUC_c. The curved contour depicts the best-fit model, and red symbols identify CYP2C8*3 genotypes. See the article by Honkalammi et al. on page 1977 of this issue.